Wall Street analyst estimates for Nkarta, Inc. (NKTX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as w...
Valuation Ratios
| Price / Book | 1.01 |
| EV / EBITDA | -2.60 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.5M | $115385 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $4.3M | $17217 | 0 | 0 | 0 | $5.9M | 0 | $9.2M |
| Gross Profit | $2.3M | $98168 | 0 | 0 | 0 | -$5.9M | 0 | -$9.2M |
| Research & Development | $4.3M | $17.2M | $36.2M | $63.4M | $90.9M | $90.9M | $96.7M | $90.4M |
| Selling, General & Admin | $2.7M | $5.2M | $15.3M | $23.0M | $28.1M | $34.9M | $31.4M | $31.6M |
| Operating Expenses | $6.9M | $22.5M | $51.5M | $86.4M | $119.0M | $125.8M | $128.2M | $112.0M |
| Operating Income | -$356449 | -$22.3M | -$51.5M | -$86.4M | -$119.0M | -$131.7M | -$128.2M | -$121.2M |
| EBITDA | -$91289 | -$20.0M | -$50.7M | -$84.3M | -$105.6M | -$120.5M | -$99.6M | -$94.9M |
| Interest Expense | 0 | $473000 | 0 | 0 | $5.6M | 0 | 0 | 0 |
| Pre-tax Income | -$274503 | -$21.1M | -$91.4M | -$86.1M | -$113.8M | -$117.5M | -$108.8M | -$104.1M |
| Income Tax | 0 | $1.8M | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$274503 | -$21.1M | -$91.4M | -$86.1M | -$113.8M | -$117.5M | -$108.8M | -$104.1M |
| EPS | $-0.01 | $-2.55 | $-1.59 | $-2.62 | $-2.61 | $-2.40 | $-1.60 | $-1.41 |
| EPS (Diluted) | $-0.01 | $-2.55 | $-1.59 | $-2.62 | $-2.61 | $-2.40 | $-1.60 | $-1.41 |
| Shares Outstanding (Diluted) | $50.3M | $9.0M | $31.8M | $32.9M | $43.6M | $49.0M | $67.9M | $74.0M |
Price
| Price | $2.87 |
| Market Cap | $205M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ALEC · APLT · CYBN · ELTX · FATE · FBRX · MOLN
Explore sector: Healthcare · Biotechnology
More sections of NKTX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks